Some take short walks, others divide large tasks into small pieces
The "best" place is simply the one that you find most comfortable and can rotate weekly to prevent skin issues
Tirzepatide for managing overweight and obesity (TA1026)
Cureus Sinha R, Papamargaritis D, Sargeant JA, Davies MJ (2023) Efficacy and safety of tirzepatide in type 2 diabetes and obesity management
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
Semaglutide has a half-life of approximately seven days, which is why weekly dosing works
